Dec 14

Artiva Named a PM360 2023 Innovative Startup

Artiva was recognized in the 2023 PM360 Innovations Issue for advancing the first allogeneic NK cell therapy to clinical trials for lupus nephritis. 

Artiva’s mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Our large-scale manufacturing process is capable of producing thousands of doses of cryopreserved, infusion-ready AlloNK cells from a single umbilical cord blood unit.

Read more about this recognition here.

Recent Posts

Artiva Biotherapeutics Receives FDA Fast Track Designation for AlloNK® in Lupus Nephritis

SAN DIEGO, February 22, 2024 — Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Artiva’s lead program AlloNK® (also known as AB-101) for the treatment of...

Artiva Named a PM360 2023 Innovative Startup

Artiva was recognized in the 2023 PM360 Innovations Issue for advancing the first allogeneic NK cell therapy to clinical trials for lupus nephritis.  Artiva’s mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Our large-scale manufacturing process is capable of producing thousands of doses of cryopreserved,...

Artiva Biotherapeutics Receives Immunology Innovation of the Year in the 2023 BioTech Breakthrough Awards Program

Artiva recognized for advancing AlloNK®, the first allogeneic, off-the-shelf NK cell therapy with an IND allowance for autoimmune disease AlloNK in combination with rituximab aims to be a safe and effective option for patients with lupus nephritis and has scalable potential for future applications in other autoimmune diseases San Diego, Calif., November 8, 2023 –...